Section

Biocon jumps after receiving SAHPRA approval for Tacrolimus capsules

By Business Standard - 7 months ago
Biocon added 3.31% to Rs 270.45 after the company has received an approval from South African Health Products Regulatory Authority (SAHPRA) for their vertically integrated, complex drug product Tacrolimus capsule in South Africa.

Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.